Roscovitine is a cyclin-dependent kinase inhibitor, which has been previously investigated
for its anticancer effects. It has also been confirmed that roscovitine can downregulate the …

BACKGROUND AND PURPOSE Roscovitine, a cyclin‐dependent kinase (CDK) inhibitor
that induces tumour cell death, is under evaluation as an anti‐cancer drug. By triggering …

Roscovitine has been reported to have anti-tumor effects in some cancer cell lines. The
phosphatidylinositol-3-kinase (PI3K) signaling, which activates protein kinase B (PKB)/Akt, is …

Exposure of human HeLaS3 cervix carcinoma cells to high doses of conventional cytostatic
drugs, eg cisplatin (CP) strongly inhibits their proliferation. However, most cytostatic agents …

Cyclin-dependent kinases (Cdks) play essential roles in the intracellular controls of the cell
cycles. Roscovitine,[2-(R)-(1-ethyl-2-hydroxyethylamino)-6-benzylamino-9-isopropylpurine] …

Abstract Roscovitine [CY-202,(R)-Roscovitine, Seliciclib] is a small molecule that inhibits
cyclin-dependent kinases (CDKs) through direct competition at the ATP-binding site. It is a …

Inhibitors of cyclin‐dependent kinases (CDKs) undergoing clinical trials as anticancer
agents usually target several CDKs in cells. Some of them are also able to increase cellular …

Purpose: Roscovitine (Rosc) is a selective inhibitor of cyclin-dependent kinases (CDKs) and
a promising therapy for various cancers. However, limited information is available on the …

Abstract Seliciclib (CYC202, R-Roscovitine) is a 2, 6, 9-substituted purine analog that is
currently in phase II clinical trials as an anticancer agent. We show in this study that R …

We have previously shown (Mgbonyebi et al., Anticancer Res., 18: 751–756, 1998) that
roscovitine, an olomoucine-related purine analogue and a selective inhibitor of cyclin …